CannaPharmaRX, Inc.
CPMD · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $4 | $0 | $0 | $0 |
| Gross Profit | -$3 | -$0 | -$0 | -$0 |
| % Margin | -357.9% | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $1 | $5 | $3 |
| SG&A Expenses | $1 | $1 | $5 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $2 | $5 | $3 |
| Operating Income | -$4 | -$2 | -$5 | -$3 |
| % Margin | -439.7% | – | – | – |
| Other Income/Exp. Net | -$6 | $5 | -$3 | -$6 |
| Pre-Tax Income | -$10 | $4 | -$9 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10 | $4 | -$9 | -$9 |
| % Margin | -1,207.8% | – | – | – |
| EPS | -0.016 | 0.012 | -0.04 | -0.12 |
| % Growth | -232.8% | 129.5% | 66.3% | – |
| EPS Diluted | -0.016 | 0.012 | -0.04 | -0.12 |
| Weighted Avg Shares Out | 625 | 309 | 211 | 75 |
| Weighted Avg Shares Out Dil | 625 | 309 | 211 | 75 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $2 | $2 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$8 | -$1 | -$5 | -$3 |
| % Margin | -931.7% | – | – | – |